Avnish leads the Portfolio Strategy and Business Development team at SystImmune. Prior to joining SystImmune Avnish gathered extensive experience in biopharma as a member of corporate venture team at Eli Lilly and leading oncology business development activities at Bristol Myers Squibb (BMS). While at BMS his team executed strategic initiatives including acquisition of Turning Point and Mirati as well as licensing deals, clinical collaborations, and equity investments in assets across modalities and stages of development.
Prior to BMS, Avnish’s professional journey included roles with increasing responsibility at Novartis and Eli Lilly leading oncology drug discovery and translational research teams. Avnish received his PhD from Mount Sinai School of Medicine in NY as a DoD fellow and post-doctoral training as a Jane Coffin Childs Fellow in the lab of Ron Depinho at MD Anderson Cancer Center.